Akebia Therapeutics, Inc. (NASDAQ:AK(BA)) has earned an average recommendation of “Hold” from the eight ratings firms that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and four have assigned a buy rating to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $9.00.
Several equities research analysts have weighed in on the company. JPMorgan Chase & Co. lowered Akebia Therapeutics from a “neutral” rating to an “underweight” rating in a research report on Friday. HC Wainwright decreased their price target on Akebia Therapeutics from $10.00 to $9.00 and set a “buy” rating for the company in a research note on Monday, October 26th. Finally, Zacks Investment Research raised Akebia Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, December 16th.
Shares of NASDAQ AK(BA) opened at $3.24 on Friday. Akebia Therapeutics has a 1-year low of $2.09 and a 1-year high of $13.71. The company has a debt-to-equity ratio of 0.24, a current ratio of 2.15 and a quick ratio of 1.67. The business’s fifty day moving average price is $3.06 and its two-hundred day moving average price is $4.99. The firm has a market capitalization of $468.31 million, a PE ratio of -1.09 and a beta of 2.11.
Akebia Therapeutics (NASDAQ:AK(BA)) last issued its earnings results on Tuesday, November 10th. The biopharmaceutical company reported ($0.42) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.17) by ($0.25). Akebia Therapeutics had a negative return on equity of 68.51% and a negative net margin of 126.86%. The company had revenue of $59.99 million during the quarter, compared to analyst estimates of $76.12 million. Equities research analysts expect that Akebia Therapeutics will post -1.77 earnings per share for the current fiscal year.
Large investors have recently added to or reduced their stakes in the stock. Private Advisor Group LLC acquired a new position in shares of Akebia Therapeutics in the 2nd quarter valued at $25,000. PNC Financial Services Group Inc. acquired a new position in shares of Akebia Therapeutics in the 2nd quarter valued at $28,000. Wedbush Securities Inc. acquired a new position in shares of Akebia Therapeutics in the 3rd quarter valued at $29,000. XTX Markets LLC acquired a new position in shares of Akebia Therapeutics in the 3rd quarter valued at $31,000. Finally, JS Capital Management LLC acquired a new position in shares of Akebia Therapeutics in the 3rd quarter valued at $37,000. Institutional investors and hedge funds own 68.98% of the company’s stock.
About Akebia Therapeutics
Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of renal therapeutics for patients with kidney diseases. The company’s lead product candidate includes Auryxia, a ferric citrate to control the serum phosphorus levels in adult patients with chronic kidney disease (CKD), on dialysis (DD)-CKD, or the hyperphosphatemia indication (HIF); and vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to CKD in DD and non-dialysis patients.
Read More: What is Blockchain?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]